New drug duo aims to tackle stubborn heart risk factor
NCT ID NCT07614984
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests an experimental drug called MK-7262, alone or with another drug called enlicitide, in 750 adults with high levels of lipoprotein(a) – a genetic risk factor for heart disease. The study compares these drugs to a placebo to see if they can safely lower both Lp(a) and LDL cholesterol over 8 weeks. Participants must already be on a stable statin dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-7262 (also known as HRS-5346) and enlicitide decanoate (also known as MK-0616)
What this could lead to
If successful, this could lead to a new treatment option for people with high lipoprotein(a), a genetic risk factor for heart disease, by lowering both Lp(a) and LDL cholesterol.
What could go wrong
This is an early Phase 2 trial, so it's not yet proven to work or be safe. The results may not apply to everyone, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIPOPROTEIN(A) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.